KBIO

 
Common Stock SEC Reporting - Current
Pink Current Information
Contact Info
  • 1000 Marina Boulevard
  • Suite 250
  • Brisbane, CA 94005-1878

Business Description


Update Company Profile
 
Financial Reporting/Disclosure
Reporting Status U.S. Reporting: SEC Reporting
Audited Financials Not Available
Latest Report Sep 30, 2016 10-Q
CIK 0001293310
Fiscal Year End 12/31
OTC Marketplace Pink Current
Profile Data
SIC - Industry Classification 2834 - Pharmaceutical preparations
Incorporated In: DE, USA
Year of Inc. 2000
Employees Not Available
Company Officers/Contacts
Cameron Durrant CEO
David Tousley Interim CFO
Morgan Lam CSO
Company Directors
Cameron Durrant Chairman
Ronald Barliant
Dale Chappell
Ezra M. Friedberg
Timothy Morris
Service Providers
Accounting/Auditing Firm

Not Available
Securities Counsel

Not Available
Investor Relations Firm

Not Available
Company History
  • Note = On December 29, 2015, KaloBios Pharmaceuticals, Inc. filed a voluntary petition for bankruptcy protection under Chapter 11 of Title 11 of the United States Bankruptcy Code. The filing was made in the United States Bankruptcy Court for the District of Delaware(Case No. 15-12628).
KBIO Security Details
Share Structure
Market Value1 $41,728,462 a/o Feb 24, 2017
Authorized Shares Not Available
Outstanding Shares 14,903,022 a/o Sep 22, 2016
-Restricted Not Available
-Unrestricted Not Available
Held at DTC Not Available
Float Not Available
Par Value Not Available
Transfer Agent(s)
Shareholders
Shareholders of Record 47 a/o Sep 01, 2016
Short Selling Data
Short Interest 2,398 (-34.87%)
Jan 31, 2017
Significant Failures to Deliver No

1Market Value calculated only for respective security